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Summary
Haemolytic anaemia is variable among patients with sickle cell anaemia
and can be estimated by reticulocyte count, lactate dehydrogenase, aspartate
aminotransferase and bilirubin levels. Using principal component analysis
of these measurements we computed a haemolytic score that we used as a
subphenotype in a genome-wide association study. We identified in one
cohort and replicated in two additional cohorts the association of a single
nucleotide polymorphism in NPRL3 (rs7203560; chr16p133)
(P = 604 9 1007). This association was validated by targeted genotyping
in a fourth independent cohort. The HBA1/HBA2 regulatory elements,
hypersensitive sites (HS)-33, HS-40 and HS-48 are located in introns of
NPRL3. Rs7203560 was in perfect linkage disequilibrium (LD) with
rs9926112 (r2 = 1) and in strong LD with rs7197554 (r2 = 075) and
rs13336641 (r2 = 077); the latter is located between HS-33 and HS-40 sites
and next to a CTCF binding site. The minor allele for rs7203560 was asso-
ciated with the /37thalassaemia gene deletion. When adjusting for HbF
and / thalassaemia, the association of NPRL3 with the haemolytic score
was significant (P = 000375) and remained significant when examining
only cases without gene deletion/ thalassaemia (P = 002463). Perhaps by
independently down-regulating expression of the HBA1/HBA2 genes, vari-
ants of the HBA1/HBA2 gene regulatory loci, tagged by rs7203560, reduce
haemolysis in sickle cell anaemia.
Keywords: haemolysis, sickle cell anaemia, haemolytic anaemia, genetic
analysis, thalassaemia.
The phenotype of sickle cell anaemia is caused by sickle vaso-
occlusion and haemolytic anaemia (Kato et al, 2007). Haem-
olysis in this disease has been associated with complications
that could result in part from vascular nitric oxide (NO)
depletion due to scavenging by free plasma haemoglobin
(Gladwin et al, 2004; Morris et al, 2005; Taylor et al, 2008).
Plasma haemoglobin is a specific marker of intravascular
haemolysis and red cell survival studies are the definitive
measurement of haemolysis. Nevertheless, these tests are
rarely done and are not available in large cohorts. However,
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haemolysis can be estimated by the reticulocyte count, lactate
dehydrogenase (LDH), aspartate aminotransferase (AST) and
bilirubin levels, all of which are commonly measured in
cohort studies, although none is specific for haemolysis (Kato
et al, 2007; Hebbel, 2011).
High concentrations of foetal haemoglobin (HbF) decrease
the polymerization tendency of sickle haemoglobin (HbS)
(reviewed in Akinsheye et al, 2011). In sickle cell anaemia
with concurrent / thalassaemia, the concentration of HbS in
sickle erythrocytes is reduced, decreasing its polymerization
tendency (reviewed in Steinberg & Embury, 1986). Both high
HbF and / thalassaemia increase the lifespan of the sickle
erythrocyte (De Ceulaer et al, 1983; Steinberg & Sebastiani,
2012). However, other genes might also affect cell life span.
We estimated the severity of haemolysis using a principal
component analysis of the commonly measured markers of
haemolysis (Gordeuk et al, 2009; Minniti et al, 2009). The
development of such a component resolves the problem of
dealing with correlated predictors in multivariate analyses,
allows for adjustment of important confounders, such as
gender, hydroxycarbamide use, age, haemoglobin levels, HbF,
a thalassaemia and site variability in laboratory assay proto-
cols and standards. The haemolytic score was associated with
intravascular haemolysis as measured by plasma haemoglobin
and red cell micro particles and had a significant inverse
relationship to total haemoglobin levels, HbF and a thalas-
saemia (Nouraie et al, 2012). Therefore, the score can be
used as a robust population-based continuous measure of
haemolytic rate and is suited for studies of genetic factors
that regulate the intensity of haemolytic anaemia in sickle
cell anaemia. We used this score as a phenotype in a gen-
ome-wide association study (GWAS).
Methods
Study participants
The patient cohort used for discovery consisted of 1 117
patients from the Cooperative Study of Sickle Cell Disease
(CSSCD; NCT00005277) homozygous for the HbS gene or
with HbS-b0 thalassaemia. Four-hundredand forty-nine
patients from the Pulmonary Hypertension and Sickle Cell
Disease with Sildenafil Therapy (Walk-PHaSST) study
(NCT00492531) and 296 patients from the Pulmonary
Hypertension and the Hypoxic Response in Sickle Cell
Disease (PUSH) study (NCT 00495638) with similar hae-
moglobin phenotypes as the discovery set were used for
replication of the discovery findings. The demographics of
these studies have been described (Gaston & Rosse, 1982;
Dham et al, 2009; Machado et al, 2011). For further vali-
dation, targeted genotyping was performed in a third
cohort of 213 additional patients with sickle cell disease
from London, UK. These studies were approved by the
Institutional Review Boards of each participating
institution.
Phenotype
We used principal component analysis to derive a haemolytic
score from reticulocyte count, LDH, AST and bilirubin using
the most informative component as previously suggested
(Gordeuk et al, 2009; Minniti et al, 2009). This score is a linear
combination of the 4 haemolytic variables with mean of 0.
Serum total bilirubin, LDH, AST, and reticulocyte counts
were measured using automated chemical and haematologic
analysers. For the CSSCD patients, longitudinal bilirubin
measurements were collected from phases 1, 2, and 3 of the
study. Only steady state measurements 4 months removed
from blood transfusion were used. The longitudinal
measurements of these study patients were analysed using a
Bayesian hierarchical mixed model that included a random
effect per patient to account for the repeated measurements,
as well as random intercept and age effects that were
allowed to vary with the clinics. The random intercept and
age effects were used to remove the between-site systematic
differences. Markov Chain Monte Carlo method in Open
bugs was used to estimate the predicted values, and
log-transformed median predicted values for each of the 4
haemolytic markers were used in the principal component
analysis (Milton et al, 2012). For the PUSH and Walk-
PHaSST patients, log transformed baseline values were used
in the principal component analysis. Patient characteristics
for the discovery, replication and validation cohorts are
shown in Table I.
Heritability of haemolysis
To examine heritability of the 4 haemolytic markers and the
haemolytic score in the CSSCD population, we examined
their correlation in 90 sibling pairs that could be identified
by identity by decent (IBD) analysis in PLINK (Purcell et al,
2007) using the genome-wide single nucleotide polymor-
phism (SNP) data. As a comparison, we randomly selected
200 unrelated pairs 1 000 times and computed average corre-
lation the 4 haemolytic markers and the haemolytic score
among unrelated individuals.
Genotyping
DNA from the CSSCD, PUSH and Walk-PHaSST samples
that formed the discovery and replication cohorts were geno-
typed using Illumina Human610-Quad SNP arrays (Illumina,
San Diego, CA, USA) with approximately 600 000 SNPs. All
samples were processed according the manufacturer’s proto-
col and Bead Studio Software was used to make genotype
calls utilizing the Illumina pre-defined clusters. Samples with
less than a 95% call rate were removed and SNPs with a call
rate <975% were re-clustered. After re-clustering, SNPs with
call rates >975%, cluster separation score >025, excess het-
erozygosity between 010 and 010, and minor allele fre-
quency >5% were retained in the analysis. We used the
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genome-wide identity by descent analysis in PLINK to dis-
cover unknown relatedness. Pairs with IBD measurements
greater than 02 were deemed to be related and related sub-
jects within individual or different studies were removed. We
also removed samples with inconsistent gender findings
defined by heterozygosity of the X chromosome and gender
recorded in the database.
Samples from the validation cohort were genotyped using
predesigned TaqMan SNP genotyping assays according to
standard Applied Biosystems protocol (Applied Biosystems,
Carlsbad, CA, USA). For each sample, 10 ng DNA was dried
in a 384-well plate, upon which was added a 5 ll reaction
volume (25 ll TaqMan universal polymerase chain reaction-
master mix, 2375 ll Sigma water, 0125 ll Assay). The sam-
ples were run on the ABI7900 under the following thermal
cycling conditions: 50°C for 2 min, 95°C for 10 min, 40
cycles of 95°C for 15 s and 60°C for 1 min. For each assay
run, 12 control samples and 3 non template controls were
included. Genotype data was exported from Sequence
Detection System (SDS) 22 software (Applied Biosystems).
In all studies, the presence of gene deletion a thalassaemia
was directly ascertained by restriction endonuclease analysis
or by multiplex polymerase chain reactions (Dozy et al,
1979; Liu et al, 2000).
Analysis
The association between haemolytic score and each SNP was
tested with multiple linear regression adjusting for age and
sex using an additive model in PLINK (Purcell et al, 2007).
Age and gender were both included as covariates as both
were significantly associated with the haemolytic score (age
P-value = 340 9 1011, sex P-value = 174 9 1011). The
minor allele was used as the coded allele in the additive
model. To assess population stratification in the CSSCD
cohort the genomic control lambda factor was calculated
Table I. Patient characteristics.
CSSCD (n = 1,117) Walk-PHaSST* (n = 449)
Variable Overall M (n = 585) F (n = 532) Overall M (n = 207) F (n = 242)
Age 1786 (1171) 1885 (1198) 1679 (1131) 3720 (1320) 3581 (1294) 3835 (1334)
Haemoglobin 211 (014) 210 (013) 212 (015) 224 (069) 226 (080) 223 (055)
Haematocrit 318 (015) 317 (014) 318 (017) 308 (251) 312 (254) 301 (251)
HbF 180 (052) 186 (051) 173 (052) 164 (148) 157 (149) 169 (146)
/ thalassaemia 370 (333%) 189 (323%) 181 (34%) 129 (301%) 56 (284%) 73 (316%)
AST 374 (029) 381 (027) 367 (020) 380 (135) 391 (053) 370 (050)
LDH 602 (022) 598 (021) 606 (023) 608 (059) 600 (059) 616 (096)
Reticulocyte 236 (040) 237 (039) 235 (040) 211 (073) 215 (073) 208 (073)
Bilirubin 113 (051) 119 (051) 108 (051) 248 (135) 267 (138) 235 (132)
Haemolytic Score† 297 9 1018 (108) 020 (153) 022 (149) 218 9 1016 (100) 029 (159) 023 (151)
PUSH (n = 296) London (n = 213)
Variable Overall M (n = 140) F (n = 156) Overall M (n = 94) F (n = 119)
Age 1185 (542) 1204 (525) 1165 (561) 3302 (1089) 3230 (1055) 3359 (1117)
Haemoglobin 222 (057) 223 (069) 222 (039) 211 (018) 217 (018) 208 (016)
Haematocrit 328 (169) 328 (181) 328 (152)
HbF 220 (198) 209 (196) 232 (197) 179 (048) 167 (047) 189 (046)
/ thalassaemia 38 (322%) 51 (4322%) 29 (2458%) 75 (35%) 28 (30%) 47 (39%)
AST 385 (040) 389 (040) 381 (039) 371 (032) 378 (033) 366 (031)
LDH 617 (048) 617 (043) 617 (053) 604 (032) 604 (035) 604 (031)
Reticulocyte 217 (073) 217 (080) 217 (067) 581 (043) 589 (032) 574 (048)
Bilirubin 099 (065) 108 (070) 091 (058) 386 (056) 400 (058) 375 (052)
Haemolytic Score 717 9 1016 (108) 021 (162) 022 (150) 182 9 1016 (106) 029 (137) 023 (132)
Summary statistics of patient characteristics in the CSSCD discovery cohort, the PUSH and WALK-PHaSST replication cohorts and in the Lon-
don validation cohort. For each cohort, the first column reports statistics (mean and standard deviate or frequencies) for all patients included in
the analysis and the second and third columns report statistics stratified by gender. Aspartate transaminase (AST), lactate dehydrogenase (LDH),
reticulocyte count, bilirubin, haemoglobin and haematocrit are reported as log transformed values in the Walk-PHaSST and PUSH cohorts and
sex, age and clinic adjusted values for the CSSCD cohort. M-male, F-female. HbF values are reported as cubic root transformed values in the
Walk-PHaSST and PUSH cohorts and sex, age and clinic adjusted values for the CSSCD cohort.
*Walk-PHaSST variables measured in SI units.
†The haemolytic score is a linear combination of the 4 haemolytic variables with mean of 0. Males have higher values than females in all 4
cohorts studied.
J. N. Milton et al
272 ª 2013 Blackwell Publishing Ltd
British Journal of Haematology, 2013, 161, 270–278
using PLINK. A meta-analysis was also performed with all 4
cohorts with Meta Analysis Helper (METAL) using the
inverse variance weighting method (http://www.sph.umich.
edu/csg/abecasis/metal). To determine if there was an associ-
ation between our top genetic variant and a thalassaemia, a
v2 test was implemented in the CSSCD cohort.
To determine the exact coordinates of the hypersensitive
site region in chromosome 16, we used the Basic Local
Alignment Search Tool (BLAST; Altschul et al, 1990) and
VISTA (Mayor et al, 2000) to compare and align sequences
in regions containing the regulatory regions of the a-globin
cluster using methods described by Hughes et al (2005). Phy-
logenetic conservation at, or near, the hypersensitive sites
was also determined (Hughes et al, 2005).
Results
Patient characteristics
Table I shows demographics, haematological data, laboratory
measures of haemolysis and the derived haemolytic score for
all 4 cohorts. Males had a higher haemolytic score compared
with females. Participants in the Walk-PHaSST study were
adults and had the highest mean age, patients in the PUSH
study were children with the lowest mean age while CSSCD
cases included both adults and children and had intermediate
ages. There was a significant association between age and the
haemolytic score (r = 0195, P-value = 340 9 1011) and
this was adjusted for in the analysis. Cooperative study of
sickle cell disease cases did not take hydroxycarbamide, 58%
of Walk-PHaSST and 44% PUSH patients were treated with
hydroxycarbamide.
The first principal component that was calculated
explained 674% of the total variance and this measurement
was used as the haemolytic score in the CSSCD cohort.
When comparing the association between the haemolytic
score and each of the 4 markers of haemolysis, as each of the
4 haemolytic markers increased the haemolytic score
increased (Fig S1). This consistency of effect across the 4
haemolytic markers indicates that the first principal compo-
nent is a good marker of haemolysis.
Heritability analysis
In the 90 sibling pairs identified in the CSSCD there was a
significant positive correlation (r = 024, P-value = 002) of
haemolytic score compared with 200 unrelated subjects,
where there was no correlation, suggesting that the haemolyt-
ic score is heritable. Table II shows similar heritability for
LDH, AST, bilirubin and reticulocyte count.
Genome-wide association study and targeted genotyping
After quality control there were 569, 554 SNPs left for the
GWAS. There was no significant correlation between the top
10 principal components and the haemolytic score, suggest-
ing no evidence for confounding by population stratification.
The Manhattan plot summarizing the results of the GWAS
is shown in Fig 1 and the results of the most significantly
associated SNPs summarized in Table III. The QQ plot in
Fig 2 shows no inflation and a genomic lambda factor of
101 was calculated, indicating that there is no confounding
due to population stratification. Although no SNP met the
108 level of genome-wide significance, rs7203560 in NPRL3
was associated with haemolytic score with a P value of
604 9 1007. Rs7203560 lies ~30 kb upstream from HS-33.
The minor allele of this NPRL3 SNP shows a protective
effect; as the number of minor alleles increases the haemolyt-
ic score decreases, reflecting decreased haemolysis. These
results were replicated in the Walk-PHaSST cohort
(b = 052, P-value = 00143).
Genome-wide data was not available in the London cohort
who were largely of African/West African/Afrocaribbean ori-
gin. In this validation cohort, rs7203560 was associated with




Sibling Pairs Unrelated Pairs
Correlation P-value Correlation P-value
AST 0559 394 9 1010 0002 04982
LDH 0307 00048 00013 04978
Serum
bilirubin
0304 00036 00054 04866
Reticulocyte
count
0495 601 9 1008 00013 0512
Haemolytic
score
024 002271 00002 05051
AST, aspartate transaminase; LDH, lactate dehydrogenase.
Fig 1. Manhattan Plot of Haemolytic Score. Manhattan plot summa-
rizing the results of the genome-wide association study of haemolytic
score with minor allele frequency >005.
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lower haemolytic score (P-value = 003674). Rs7203560 was
not as highly associated with the 4 haemolytic markers indi-
vidually after adjusting for age and gender in the CSSCD
cohort (Table IV). These results suggest that using a sum-
mary trait (haemolytic score) allows us to have more power
to detect traits that are associated with all 4 of the haemolyt-
ic variables with consistent effects in comparison to perform-
ing 4 individual GWAS.
Four SNPs in olfactory receptor (OR) genes on
chromosome chr11p; and OR51L2 (rs1391617: b = 017,
P-value = 00003), OR51L1 (rs2445284: b = 042,
P-value = 739 9 1005), OR51L1/OR51L2 rs7938426:
b = 021, P-value = 608 9 1005, rs7948471: b = 021,
P-value = 587 9 1005) were associated with the haemo-
lytic score although below the generally accepted level for
genome-wide significance. These results were replicated in
the Walk-PHaSST and PUSH cohorts and rs794847 in
OR51L1/OR51L2 was validated in the London cohort
(Table III).
When a meta-analysis of genome-wide data was done,
rs7203560 and OR receptor polymorphisms all met genome-
wide significance levels (Table III).
Two SNPs located in BCL11A (rs766432: b = 022,
P-value = 927 9 1007; rs10195871: b = 018, P-value =
Fig 2. QQ plot from CSSCD for single nucleotide polymorphisms-
with minor allele frequency >005.
Table III. SNPs associated with haemolytic score.
Variant information Meta- analysis CSSCD





allele MAF b SE P-value b SE P-value
rs7203560 16 NPRL3 184390 C A 007 044 007 206 9 1009 044 009 604 9 1007
rs7948471 11 OR51I2,OR51I1 5471746 A G 021 026 004 303 9 1010 021 005 587 9 1005
rs7938426 11 OR51I2,OR51I1 5471832 G A 021 025 004 109 9 1008 021 005 608 9 1005
rs2445284 11 OR51L1 5029703 G A 005 082 007 134 9 1029 042 010 739 9 1005
Variant information Walk-PHaSST PUSH London





allele MAF b SE P-value b SE P-value b SE P-value
rs7203560 16 NPRL3 184390 C A 007 053 022 0014 013 031 0672 042 020 00367
rs7948471 11 OR51I2,
OR51I1
5471746 A G 021 035 011 0002 039 014 0004 046 015 0017
rs7938426 11 OR51I2,
OR51I1
5471832 G A 021 037 011 00012 039 014 0004 NA NA NA
rs2445284 11 OR51L1 5029703 G A 005 132 015 160 9 1017 175 017 301 9
1021
041 028 0146
Single nucleotide polymorphisms (SNPs) meeting significance threshold (5 9 1004) in the CSSCD study that replicate in the three independent
cohorts. The table reports the SNP identifier from dbSNP, chromosome (Chr), physical coordinates [human genome (hg)19], the coded allele in
PLINK (also minor allele) and the non-coded allele, the minor allele frequency (MAF), the gene clusters where the SNP is located, and regression
coefficient (b), standard error (SE) and P-value in each study. Additive models of association were used in all studies adjusting for age and
gender. bp denotes position of the SNP according to hg19 coordinates.
Table IV. Association of rs7203560 with four haemolytic markers.
Haemolytic Marker b Standard Error P-value
Reticulocyte count 015 003 512 9 1006
Serum bilirubin 009 004 00099
LDH 007 002 00003
AST 007 002 00026
The association of rs7203560 with each of the 4 haemolytic markers
individually using an additive model and adjusting for age and gen-
der using data from the CSSCD.
AST, aspartate transaminase; LDH, lactate dehydrogenase.
J. N. Milton et al
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987 9 1005) that were associated with HbF in sickle cell anae-
mia in a previous GWAS were also associated with haemolytic
score (Solovieff et al, 2010).
Eight SNPs had regression coefficients in the same direc-
tion in the CSSCD cohort and the Walk-PHaSST and PUSH
cohorts. The results for the annotated SNPs are shown in
Table III.
Linkage disequilibrium patterns
We hypothesized that rs7203560 is a marker for genetic
variants in or near the hypersensitive site regions that are
known to regulate expression of the HBA1/HBA2 genes
(Fig 3).
Using Haploview, Barrett et al (2005), rs7203560 was in
perfect linkage disequilibrium (LD) with rs9926112 (r2 = 1)
and in strong LD with rs7197554 (r2 = 075) and rs13336641
(r2 = 077). SNPs rs7197554 and rs9926112 are located
approximately 10 kb upstream from the HS-33 site and
rs13336641 is located approximately 3–4 kb upstream from
HS-40 and right at the edge of CTCF and other transcription
factor binding sites (ENCODE data). While we were able to
determine that rs7203560 was in high LD with SNPs near the
HS regions, we were unable to determine if our top SNP was
in LD with SNPs in the HS regions due to the low minor
allele frequencies of these SNPs. Resequencing is required to
determine if the haemolytic score is associated with novel
variants in the HS region.
Effects of / thalassaemia and HbF
As the number of minor alleles of rs7203560 increases from
0 to 1 to 2, the odds of at least one HBA1/HBA2 deletion
(a37) increases (033 to 218 to 3, respectively; v22 = 9732,
P-value <00001). The odds of having at least one HBA1/
HBA2 deletion is 039 for individuals without a copy of the
rs7203560 protective allele and is 223 for individuals with a
copy of the protective allele (v21 = 10615, P-value <00001).
To determine if the association seen between rs7203560 and
the haemolytic score was a result of gene deletion / thalas-
saemia, a 2-way analysis of variance was performed including
the interaction between rs7203560 and / thalassaemia. The
interaction was not significant (v1
2 = 023, P-value =04623)
and the lack of interaction shows that a thalassaemia does
not modify the association between the haemolytic score and
rs7203560.
There was a significant association between HbF and the
haemolytic score after adjusting for / thalassaemia status
(b = 004, P-value = 400 9 1013). After adjusting for
HbF and / thalassaemia in a GWAS, rs7203560 remained
significantly associated with the haemolytic score
(b = 028, P-value = 000375) indicating that the associa-
tion between this SNP and the haemolytic score is not solely
due to gene deletion / thalassaemia and HbF. When we
removed patients who had at least one HBA1/HBA2 deletion
the association between rs7203560 and the haemolytic score
remained significant (P-value = 002463).
Fig 3. Location of the a-globin regulatory elements (blue brackets) within introns of NPRL3 and the linkage disequilibrium patterns of
rs7203560 according to HapMap. Rs7203560 is circled in yellow. Circled in red are single nucleotide polymorphisms (SNPs) for which it was
possible to calculate linkage disequilibrium. The allele frequencies for the SNPs are as follows: 0139 for rs7203560, 0175 for rs13336641, 0175
for rs9926112 and 0219 for rs7197554.
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Discussion
A composite variable derived from readily available markers
of haemolysis was used as a subphenotype of sickle cell anae-
mia in a GWAS. This approach to estimating haemolysis was
recently validated by showing that the haemolytic score was
significantly associated with plasma red blood cell micro par-
ticles and cell-free haemoglobin concentration, both of which
are more direct markers of intravascular haemolysis in sickle
cell disease (Cannan, 1958; Reiter et al, 2002; Nouraie et al,
2012). As the baseline rate of haemolysis in an individual
with sickle cell anaemia is stable over time, it is a suitable
subphenotype in a genetic association study (Taylor et al,
2008).
Some complications of sickle cell anaemia more often
appear in patients with high rates of haemolysis (Kato et al,
2007; Taylor et al, 2008). Among these are stroke, leg ulcers,
sickle nephropathy, priapism and sickle vasculopathy, esti-
mated by the tricuspid regurgitant jet velocity (TRV). All
have been used as subphenotypes in genetic association stud-
ies (reviewed in Steinberg & Sebastiani, 2012). a Thalassae-
mia reduces the risk of all these complications, while the
degree of protection afforded by a high HbF level is less clear
(Steinberg & Sebastiani, 2012). Insufficient power was pres-
ent to detect an association of rs7203560 with individual dis-
ease subphenotypes associated with haemolysis because of
the very small numbers of patients having these complica-
tions who were homozygous for the minor allele (data not
shown).
Focused genotyping of candidate genetic modifiers of
selected subphenotypes have shown that polymorphisms in
TGFBR3 and a few other genes have been associated with the
haemolysis-associated subphenotypes. These results have not
been replicated by GWAS. This is likely to be a result of the
small effects of these polymorphisms on a subphenotype that
then requires a very large number of cases to meet the strin-
gent significance levels needed when hundreds of thousands
of comparisons are being made. It has not yet been possible
to assemble cohorts of the requisite size in a rare disorder
like sickle cell anaemia.
Rs7203560, a SNP in the first intron of NPRL3 (Nitrogen
Permease Regulator-Like 3; C16orf35; chr 16p133) was most
significantly associated with haemolytic score. NPRL3 is
highly conserved and upstream of the human HBA1/HBA2
gene cluster in all vertebrates examined. (Hughes et al, 2005)
Its functions are unknown, although, its deletion causes
embryonic lethality from multiple cardiovascular defects
(Kowalczyk et al, 2012). Within introns of NPRL3 lie the
HBA1/HBA2 gene regulatory elements, HS-48, HS-40 and
HS-33 that are required for HBA1/HBA2 gene expression
(Hughes et al, 2005). SNPs very close to the HBA1/HBA2
regulatory elements are in strong LD with rs7203560. Also
located between HS-33 and HS-40 adjacent to rs1333664 is a
CTCF binding site. CTCF is a conserved zinc finger protein
with many regulatory functions (Phillips & Corces, 2009).
We therefore hypothesize that rs7203560 is a marker for one
or more variants in or near the HBA1/HBA2 gene regulatory
elements that down-regulateHBA1/HBA2 gene expression
causing a mild a thalassaemia-like effect. The functional basis
for this effect is unknown although it has recently become
apparent that polymorphisms in DNase I hypersensitive sites
and other regulatory regions play a critical role in defining
gene expression (Maurano et al, 2012). The minor allele fre-
quency (MAF) of rs7203560 is 0139 in the HapMapYoruban
population; however, it has a MAF of 0 in the HapMap Cen-
tral European population. This suggests that, like gene dele-
tion a thalassemia, genetic elements marked by rs7203560
SNP could confer a selective advantage in populations with a
high prevalence of malaria.
A meta-analysis of 24 167 individuals of European ances-
try and 14 700 Japanese, found SNPs in ITFG3 that were
associated with mean corpuscular volume (MCV) and mean
corpuscular haemoglobin (MCH) (Ganesh et al, 2009; Kama-
tani et al, 2010). ITFG3 (integrin alpha FG-GAP repeat con-
taining 3; C16orf9; 16p133) is downstream of HBA1 and
412 kb from rs7203560. Down-regulating HBA1/HBA2 gene
expression should reduce MCV; however, because of the rela-
tively small number of patients we studied we were unable to
show a relationship between rs7203560 and MCV.
Six haplotypes of the HS-40 region have been described
and haplotypes A and D are most prevalent in individuals of
African origin (Harteveld et al, 2002). The common a37
deletion is found on several of these haplotypes. Whether or
not HS-40 haplotypes affect HBA1/HBA2 gene expression, as
reflected by the a/b globin biosynthesis ratios, or alter the
properties of erythrocytes, estimated by MCV and MCH,
have not been definitively determined. Expression of a lucif-
erase reporter in K562 cells was greatest when the enhancer
was the 350 bp core element of the A haplotype of HS-40
(Ribeiro et al, 2009). The relationship of haplotypes of HS-40
—haplotypes of other HBA1/HBA2 gene regulatory elements
have yet to be described— to rs7203560 is unknown.
In conclusion, a SNP in NPRL3 was independently asso-
ciated with haemolysis in sickle cell anaemia and was in
LD with regions of the genome that regulate HBA1/HBA2
gene expression. Perhaps by independently down-regulating
expression of the HBA1/HBA2 genes, variants of the
HBA1/HBA2 gene regulatory loci, tagged by the NPRL3
SNP, rs7203560, reduce haemolysis in sickle cell anaemia.
As intravascular haemolysis plays an important role in the
pathophysiology of sickle cell disease and other diseases where
chronic haemolysis is present, like malaria, and in the lesion
associated with blood storage, understanding further the
genetic basis of red cell destruction has potential therapeutic
implications (Rother et al, 2005; Gladwin et al, 2012).
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